global-alert
global messaging alerts
Advancing Fill-Finish Technologyto Serve the World
Trinity Capital Commits $35 Million in Equipment Financing to ApiJect

Trinity Capital Commits $35 Million in Equipment Financing to ApiJect

Our company has been recognized and awarded for our technology and innovation.

"Transitioning your Drug Products or Vaccines into a Prefilled Blow-Fill-Seal Delivery Device"

Register Today for a No Cost Webinar Hosted by XTalks

Environmental Study

Greenhouse Emissions and Environmental Footprint Reduced Significantly by Innovative Medical Device

Peer Reviewed Study Shows BFS Prefilled Injectors have Lower Environmental Footprint than Widely Used Glass Options

previous arrow
next arrow

We bring together Blow-Fill-Seal and injection-molding technology so that pharmaceuticals and vaccines can be fill-finished in single-dose prefilled injectors at any scale.

Drug Delivery
Drug Delivery
Drug Delivery

At ApiJect, we work with pharmaceutical companies to improve how they can fill-finish injectable medicines. Together, we create scalable, cost-efficient drug delivery systems, and assist companies in manufacturing those devices at their facilities or a trusted contract manufacturer.

Details
Platform
Platform
Platform

The ApiJect Platform brings together Blow-Fill-Seal (BFS) aseptic drug packaging with connectable components to create high-quality, prefilled drug delivery systems that can be made at development and commercial scale once approved by appropriate regulators.

Details
Licensing
Licensing
Licensing

We license our technology to help pharma companies and CDMOs around the world efficiently fill-finish their injection drug products in our delivery systems. Our services include drug-specific BFS mold and device design licensing, device design and development, prototype development, and BFS production support.

Details
Design & Engineering
R&D
Design & Engineering

ApiJect engineers have made advances with BFS by developing proprietary temperature management methods that can potentially enable BFS fill-finish of many temperature-sensitive biologics and vaccines that are not possible on standard BFS lines. Our experts employ a variety of techniques to consistently manage the drug product’s temperature throughout the fill-finish process.

Details

homepage_video_still

Discover how ApiJect is reinventing injectables for the world.

Social media & sharing icons powered by UltimatelySocial
Twitter
YouTube
YouTube
LinkedIn
LinkedIn